|
Market Cap (5-Jul) $6,838,995 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0 |
IXC released this announcement to the ASX on 20 October 2020, 13:08. The announcement is not marked as price sensitive, and is 16 page(s) in length and 400.75kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.185% short sold according to ASIC data. It was ranked the 365th most shorted stock on the ASX. It remains ranked 521st as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 20 April 2023, 8:52 |
| Israel Ministry of Health Approval for IIH EVOLVE | 20 April 2023, 8:12 |
| March Appendix 4C and Investor Conference Call Details | 17 April 2023, 17:34 |
| Appendix 3G | 20 October 2020, 13:08 |
| There has been no announcements made to the ASX since this one. |
You must be logged in to post a reply.
Invex Therapeutics Ltd 